Endologix to Present at Two Upcoming Conferences

IRVINE, Calif., Nov. 29, 2010 /PRNewswire-FirstCall/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today that John McDermott, President and Chief Executive Officer, is scheduled to present at two upcoming investor conferences. The first presentation will be at the 22nd Annual Piper Jaffray Health Care Conference in New York.

Event: 22nd Annual Piper Jaffray Health Care Conference  
Date: Tuesday, November 30, 2010  
Time: 10:00 a.m. ET / 7:00 a.m. PT

The second presentation will be at the 5th Annual Canaccord Genuity Cardiovascular, Diabetes & Obesity Conference in San Francisco.

Event: 5th Annual Canaccord Genuity Cardiovascular, Diabetes & Obesity Conference  
Date: Tuesday, December 7, 2010  
Time: 1:00 p.m. ET / 10:00 a.m. PT

An audio Web cast of the Company's presentations will be available by visiting the investor relations section of Endologix's Web site at www.endologix.com. A replay of the presentations will be available for 30 days.

About Endologix, Inc.

Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's flagship product is the Powerlink® System, which is an endovascular stent graft for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it a leading cause of death in the U.S. Additional information can be found on Endologix's Web site at www.endologix.com.

SOURCE Endologix, Inc.

News Provided by Acquire Media